Metabolic tumour volume refined treatment selection in early NK/T-cell lymphom
An MTV threshold of 50 mL identified patients with poorer survival who appeared to benefit from combined-modality treatment.
Tag
non-hodgkin
Concurrent polatuzumab vedotin and radiotherapy showed no unexpected toxicity in B-cell lymphoma
Concurrent polatuzumab vedotin and radiotherapy was feasible in heavily pretreated aggressive B-cell lymphoma without unexpected acute or subacute toxicity.
Sandwich chemoradiotherapy showed favorable local control in early natural killer/T-cell lymphoma
Three-year locoregional recurrence-free survival was 90.8%, with most locoregional recurrences occurring within or near the radiation field.